Stability of the CMI-ALS axis in prostate cancer patients: a new target for prognostic assessment and treatment optimization

Background: The Cardiometabolic index (CMI) is used to assess individual cardiovascular metabolic health status and risk of metabolic disorders. Allostatic load score (ALS) quantifies the body’s physiological response to stress. This study aimed to investigate the relationship between the CMI and ALS in patients with prostate cancer using data from the National Health and Nutrition Examination Survey (NHANES). Methods: A total of 139 patients with prostate cancer were included in the analysis. Receiver operating characteristic (ROC) curve and decision curve analysis (DCA) were employed to assess the predictive accuracy and clinical net benefit. Multivariate linear regression was conducted to evaluate the relationship between CMI and ALS. Additionally, various analytical techniques, including quantile regression and logistic regression, were utilized to verify the stability and independence of their relationship. Collinearity, partial correlation, stepwise linear regression, multivariate regression, and mediation effect analyses were performed to examine whether the shared factor high-density lipoprotein cholesterol (HDL-C) influenced the CMI-ALS relationship. Results: The area under the curve (AUC) for CMI in predicting ALS was 0.650, indicating CMI can distinguish positive and negative samples more accurately than a random guess (AUC: 0.500), and has predictive ability. DCA indicated a clinical net benefit within the threshold probability range of 0.25 to 0.61. A positive relationship between CMI and ALS was observed (β [95% Confidence interval (CI)]: 0.598 [0.319, 0.877]). The relationship was found to be both stable and independent (all p < 0.05), unaffected by confounding factors. Furthermore, this relationship was not attributable to shared variables, confirming that CMI independently contributed to ALS (all p < 0.05). Conclusions: The study demonstrated a positive relationship between CMI and ALS in patients with prostate cancer. The find highlights the importance of monitoring CMI in those patients for early clinical intervention to mitigate allostatic load.

Prostate cancer; Cardiometabolic index; Allostatic load; Inflammation

[1] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024; 74: 229–263.

[2] Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, et al. Recent patterns and trends in global prostate cancer incidence and mortality: an update. European Urology. 2025; 87: 302–313.

[3] Chiefari M, Eziandio C. Metabolic disorders in cancer patients. Tumori Journal. 2001; 87: 82–84.

[4] Peng Q, Shen Y, Xu Y, Feng Z, Xu Y, Wang Y, et al. Association of metabolic dysregulation with treatment response in rectal cancer patients undergoing chemoradiotherapy. BMC Medical Genomics. 2025; 18: 48.

[5] Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. Journal of Urology. 2013; 189: S34–S42; discussion S43–S44.

[6] Keating NL, O’Malley A, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. JNCI: Journal of the National Cancer Institute. 2012; 104: 1518–1523.

[7] Yin LJ, Wang XH. Research advance in the effects of androgen and its receptor on the development of obesity, obesity-related diseases and disorders of glucose and lipid metabolism. Acta Physiologica Sinica. 2018; 70: 319–328. (In Chinese)

[8] Guerrios-Rivera L, Howard LE, Wiggins EK, Hoyo C, Grant DJ, Erickson TR, et al. Metabolic syndrome is associated with aggressive prostate cancer regardless of race. Cancer Causes & Control. 2023; 34: 213–221.

[9] Drab A, Wdowiak K, Kanadys W, Zajączkowski K, Koczkodaj P, Religioni U, et al. Diabetes mellitus and prostate cancer risk—a systematic review and meta-analysis. Cancers. 2024; 16: 4010.

[10] Alberto M, Yim A, Lawrentschuk N, Bolton D. Dysfunctional lipid metabolism—the basis for how genetic abnormalities express the phenotype of aggressive prostate cancer. Cancers. 2023; 15: 341.

[11] Yu C, Hu W, Lei X. Association between cardiometabolic index (CMI) and suicidal ideation: the mediating role of depression and cardiovascular disease. Journal of Affective Disorders. 2025; 380: 487–495.

[12] Wakabayashi I, Daimon T. The “cardiometabolic index” as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clinica Chimica Acta. 2015; 438: 274–278.

[13] Lazzer S, D’Alleva M, Isola M, De Martino M, Caroli D, Bondesan A, et al. Cardiometabolic Index (CMI) and Visceral Adiposity Index (VAI) highlight a higher risk of metabolic syndrome in women with severe obesity. Journal of Clinical Medicine. 2023; 12: 3055.

[14] McCrory C, Fiorito G, Ni Cheallaigh C, Polidoro S, Karisola P, Alenius H, et al. How does socio-economic position (SEP) get biologically embedded? A comparison of allostatic load and the epigenetic clock(s). Psychoneuroendocrinology. 2019; 104: 64–73.

[15] Obeng-Gyasi S, Li Y, Carson WE, Reisenger S, Presley CJ, Shields PG, et al. Association of allostatic load with overall mortality among patients with metastatic non-small cell lung cancer. JAMA. 2022; 5: e2221626.

[16] Mira RS. The relationship between allostatic load and progress of multimorbidity among older americans. Innovation in Aging. 2023; 7: 1138–1139.

[17] Hu S, Chang CP, Dodson MW, Deshmukh V, Newman M, Date A, et al. Endocrine and metabolic diseases among survivors of prostate cancer in a population-based cohort. Journal of Clinical Oncology. 2024; 42: 306.

[18] Lifshitz K, Ber Y, Margel D. Role of metabolic syndrome in prostate cancer development. European Urology Focus. 2021; 7: 508–512.

[19] Dai Z, Zhou X. Associations between allostatic load and hepatic steatosis and liver fibrosis: evidence from NHANES 2017–2020. BMC Public Health. 2024; 24: 1602.

[20] Du EY, Jiang K, Carlson MC, Reed NS, Deal JA. Hearing impairment and allostatic load in older adults. JAMA Otolaryngology—Head & Neck Surgery. 2023; 149: 597–606.

[21] Petrova D, Ubago-Guisado E, Garcia-Retamero R, Redondo-Sánchez D, Pérez-Gómez B, Catena A, et al. Allostatic load and depression symptoms in cancer survivors: a national health and nutrition examination survey study. Cancer Nursing. 2024; 47: 290–298.

[22] Kim S. Overview of cotinine cutoff values for smoking status classification. International Journal of Environmental Research and Public Health. 2016; 13: 1236.

[23] Wang M, Lu X, Zheng X, Xu C, Liu J. The relationship between sleep duration and thyroid function in the adult US population: NHANES 2007–2012. PLOS ONE. 2023; 18: e0291799.

[24] Voora R, Hinderliter AL. Modulation of sympathetic overactivity to treat resistant hypertension. Current Hypertension Reports. 2018; 20: 92.

[25] Szablewski L. Insulin resistance: the increased risk of cancers. Current Oncology. 2024; 31: 998–1027.

[26] Seeman T, Gruenewald T, Karlamangla A, Sidney S, Liu K, McEwen B, et al. Modeling multisystem biological risk in young adults: the coronary artery risk development in young adults study. American Journal of Human Biology. 2010; 22: 463–472.

[27] Li Y, Zhang J, Zheng X, Lu W, Guo J, Chen F, et al. Depression, anxiety and self-esteem in adolescent girls with polycystic ovary syndrome: a systematic review and meta-analysis. Frontiers in Endocrinology. 2024; 15: 1399580.

[28] McEwen BS. Neurobiological and systemic effects of chronic stress. Chronic Stress. 2017; 1: 2470547017692328.